Details der Publikation - Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

Abstract The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available..

Medienart:	E-Artikel

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	Zur Gesamtaufnahme - volume:14
Enthalten in:	Frontiers of medicine - 14(2020), 5 vom: 03. Juli, Seite 601-612

Sprache:	Englisch

Beteiligte Personen:	Xu, Jiuyang [VerfasserIn] Huang, Chaolin [VerfasserIn] Fan, Guohui [VerfasserIn] Liu, Zhibo [VerfasserIn] Shang, Lianhan [VerfasserIn] Zhou, Fei [VerfasserIn] Wang, Yeming [VerfasserIn] Yu, Jiapei [VerfasserIn] Yang, Luning [VerfasserIn] Xie, Ke [VerfasserIn] Huang, Zhisheng [VerfasserIn] Huang, Lixue [VerfasserIn] Gu, Xiaoying [VerfasserIn] Li, Hui [VerfasserIn] Zhang, Yi [VerfasserIn] Wang, Yimin [VerfasserIn] Hayden, Frederick G. [VerfasserIn] Horby, Peter W. [VerfasserIn] Cao, Bin [VerfasserIn] Wang, Chen [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.00 / Medizin: Allgemeines / Medizin: Allgemeines
Themen:	Angiotensin II receptor blocker Angiotensin-converting enzyme inhibitor COVID-19 Hypertension SARS-CoV-2

Anmerkungen:	© Higher Education Press 2020

doi:	10.1007/s11684-020-0800-y

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC212020862X

Internformat


LEADER	01000caa a22002652 4500
001	OLC212020862X
003	DE-627
005	20240403145325.0
007	cr uuu---uuuuu
008	230504s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11684-020-0800-y \|2 doi
035			\|a (DE-627)OLC212020862X
035			\|a (DE-He213)s11684-020-0800-y-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a 44.00 \|2 bkl
100	1		\|a Xu, Jiuyang \|e verfasserin \|4 aut
245	1	0	\|a Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Higher Education Press 2020
520			\|a Abstract The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available.
650		4	\|a COVID-19
650		4	\|a SARS-CoV-2
650		4	\|a hypertension
650		4	\|a angiotensin-converting enzyme inhibitor
650		4	\|a angiotensin II receptor blocker
700	1		\|a Huang, Chaolin \|4 aut
700	1		\|a Fan, Guohui \|4 aut
700	1		\|a Liu, Zhibo \|4 aut
700	1		\|a Shang, Lianhan \|4 aut
700	1		\|a Zhou, Fei \|4 aut
700	1		\|a Wang, Yeming \|4 aut
700	1		\|a Yu, Jiapei \|4 aut
700	1		\|a Yang, Luning \|4 aut
700	1		\|a Xie, Ke \|4 aut
700	1		\|a Huang, Zhisheng \|4 aut
700	1		\|a Huang, Lixue \|4 aut
700	1		\|a Gu, Xiaoying \|4 aut
700	1		\|a Li, Hui \|4 aut
700	1		\|a Zhang, Yi \|4 aut
700	1		\|a Wang, Yimin \|4 aut
700	1		\|a Hayden, Frederick G. \|4 aut
700	1		\|a Horby, Peter W. \|4 aut
700	1		\|a Cao, Bin \|4 aut
700	1		\|a Wang, Chen \|4 aut
773	0	8	\|i Enthalten in \|t Frontiers of medicine \|d Higher Education Press, 2011 \|g 14(2020), 5 vom: 03. Juli, Seite 601-612 \|h Online-Ressource \|w (DE-627)664261027 \|w (DE-600)2617113-2 \|w (DE-576)370704541 \|x 2095-0225 \|7 nnns
773	1	8	\|g volume:14 \|g year:2020 \|g number:5 \|g day:03 \|g month:07 \|g pages:601-612
856	4	0	\|u https://dx.doi.org/10.1007/s11684-020-0800-y \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2433
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.00 \|j Medizin: Allgemeines \|j Medizin: Allgemeines \|q VZ
951			\|a AR
952			\|d 14 \|j 2020 \|e 5 \|b 03 \|c 07 \|h 601-612

Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände